Просмотр исходного текста страницы A Very Simple Miracle Strategy For MCC950

We describe here the detailed epidemiology, management and prognosis in the subgroup of patients with Candida peritonitis. AmarCand�� was a prospective, multicentre, French observational study involving adult ICU patients with invasive Candida infection requiring a systemic antifungal therapy [11]. Criteria used for diagnosis were those proposed [http://en.wikipedia.org/wiki/PRDX5 PRDX5] by the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer [12]. In accordance with French law, approval of an ethics committee was not required. However, all patients gave informed consent to participate and procedures were in accordance with the Helsinki Declaration. A scientific committee (the authors) independently designed the study, and reviewed the data. For each episode of Candida peritonitis, demographic characteristics, underlying diseases and severity of illness were compared with the other patients in the Amarcand cohort. Empiric antifungal treatment, interventions associated with antifungal treatment and risk factors for death were assessed in cases of Candida peritonitis [11]. Peritonitis was diagnosed on the basis of macroscopic findings and direct examination or positive culture for Candida of the peritoneal fluid collected during operation. Candidaemia was defined [http://www.selleckchem.com/products/midostaurin-pkc412.html selleck] by at least one positive blood culture. Candida peritonitis was considered as nosocomial if diagnosed ��48?h after hospitalization or community-acquired ([http://www.selleckchem.com/products/mcc950-sodium-salt.html learn more] (R) to antifungals according to CLSI interpretative categories (http://www.clsi.org). Empiric treatment was classified as inadequate if at least one Candida strain was resistant or SDD (fluconazole